Tuesday, December 29, 2020 8:42:09 AM
loved how everyone was hatting this company at $9.00 2 month later its 20 so much cash and partnerships 30.00 target next year loaded up for more upside on SGMO & HGEN favorite two gene editing stocks both in phase 3
SGMO
https://www.businesswire.com/news/home/20201207005251/en/Pfizer-and-Sangamo-Announce-Updated-Phase-12-Results-Showing-Sustained-Factor-VIII-Activity-Levels-in-3x1013-VGKG-Cohort-Through-One-Year-Following-Hemophilia-A-Gene-Therapy
Humanigen Secures Exclusive Worldwide License to Gene-Editing Technology from Mayo Clinic to Improve CAR-T
Expands Humanigen’s intellectual property portfolio to include gene-edited CAR-T cells
Builds and further strengthens Humanigen’s leadership position in GM-CSF neutralization
$SGMO
SGMO
https://www.businesswire.com/news/home/20201207005251/en/Pfizer-and-Sangamo-Announce-Updated-Phase-12-Results-Showing-Sustained-Factor-VIII-Activity-Levels-in-3x1013-VGKG-Cohort-Through-One-Year-Following-Hemophilia-A-Gene-Therapy
Humanigen Secures Exclusive Worldwide License to Gene-Editing Technology from Mayo Clinic to Improve CAR-T
Expands Humanigen’s intellectual property portfolio to include gene-edited CAR-T cells
Builds and further strengthens Humanigen’s leadership position in GM-CSF neutralization
$SGMO
Recent SGMO News
- How Advanced Drug Delivery Could Improve Existing Cancer Treatments • GlobeNewswire Inc. • 06/01/2026 12:30:00 PM
- Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2026 Financial Results • GlobeNewswire Inc. • 05/14/2026 08:01:00 PM
- Sangamo Therapeutics Announces First Quarter 2026 Earnings Call • GlobeNewswire Inc. • 05/11/2026 08:05:00 PM
- Sangamo Therapeutics to Present Pipeline and Technology Advances at the 29th Annual Meeting of The American Society of Gene & Cell Therapy (ASGCT) • GlobeNewswire Inc. • 04/30/2026 12:05:00 PM
- Sangamo Therapeutics (SGMO) Nasdaq delisting shifts stock to OTCQB market • IH Market News • 04/29/2026 02:45:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/29/2026 12:37:29 PM
- Sangamo Therapeutics Announces Transition to Trading on OTCQB Venture Market • GlobeNewswire Inc. • 04/29/2026 12:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/23/2026 08:07:12 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/23/2026 08:05:40 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 04/22/2026 08:01:11 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 04/06/2026 11:08:08 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/03/2026 08:15:20 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/03/2026 08:15:19 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/03/2026 08:15:16 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/03/2026 08:15:15 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/03/2026 08:15:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/30/2026 09:29:20 PM
- Sangamo Therapeutics Reports Recent Business Highlights And Fourth Quarter And Full Year 2025 Financial Results • GlobeNewswire Inc. • 03/30/2026 08:01:00 PM
- Sangamo Therapeutics Announces Fourth Quarter and Full Year 2025 Earnings Call • GlobeNewswire Inc. • 03/19/2026 08:03:00 PM
- Sangamo Therapeutics Advances Rolling Submission of BLA to U.S. FDA for ST-920 in Fabry Disease • GlobeNewswire Inc. • 03/09/2026 12:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/27/2026 02:40:15 AM
